Sugi Predict

Sugi Predict / Compounds / SCHEMBL7891196

SCHEMBL7891196

SCHEMBL7891196

Nc1nc2cc(B(O)O)ccc2o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.58
▸ LMNA P02545 1/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ THRB P10828 1/20 0.58
▸ ALOX15 P16050 1/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ ENPP2 Q13822 2/20 0.47
▸ PIK3CG P48736 2/20 0.44
▸ PIK3CA P42336 6/20 0.40
▸ PIK3CB P42338 2/20 0.40
▸ PIK3CD O00329 1/20 0.40
▸ MTOR P42345 5/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ GFER P55789 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954485 1.00 MAPT (0.58) MAPTLMNACYP1A2THRBALOX15
Hydrochloric Acid SCHEMBL22494312 0.98 LMNA (0.56) MAPTLMNACYP1A2THRBALOX15
Hydrochloric Acid SCHEMBL28510580 0.98 LMNA (0.56) MAPTLMNACYP1A2THRBALOX15
SCHEMBL31394658 0.87 PIK3CG (0.56) MAPTLMNACYP1A2THRBALOX15
SCHEMBL7893637 0.87 PIK3CG (0.56) MAPTLMNACYP1A2THRBALOX15
SCHEMBL18727431 0.82 LMNA (0.50) MAPTLMNACYP1A2THRBALOX15
SCHEMBL15445621 0.78 L3MBTL1 (0.53) MAPTLMNAMAPK1ENPP2NPC1
SCHEMBL29952498 0.78 L3MBTL1 (0.53) MAPTLMNAMAPK1ENPP2NPC1
SCHEMBL4473998 0.77 LMNA (0.61) MAPTLMNACYP1A2THRBALOX15
SCHEMBL12850681 0.76 LMNA (0.66) MAPTLMNACYP1A2THRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108530436-B Pyrazole compound and preparation method and application thereof 黄传满 2020-12-29 — — CN claimed
US-20240262836-A1 NOVEL MTOR INHIBITOR COMPOUNDS GALDERMA HOLDING S.A. (CH) 2024-08-08 — — US disclosed
EP-4396188-A1 NOVEL MTOR INHIBITOR COMPOUNDS Galderma Holding SA (CH) 2024-07-10 — — EP disclosed
WO-2023199196-A1 SALTS FOR MTOR COMPOUNDS Galderma Holding SA (CH) 2023-10-19 — — WO disclosed
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof MILLENNIUM PHARMACEUTICALS, INC. 2023-10-12 — — US disclosed
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof MILLENNIUM PHARMACEUTICALS, INC. 2023-10-12 — — US disclosed
WO-2023031738-A1 NOVEL MTOR INHIBITOR COMPOUNDS Galderma Holding SA (CH) 2023-03-09 — — WO disclosed
WO-2023285926-A1 SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS Galderma Holding SA (CH) 2023-01-19 — — WO disclosed
US-11547697-B2 Heterocyclic compounds and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2023-01-10 — — US disclosed
EP-3153023-B1 BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE TAKEDA PHARMACEUTICALS CO (JP) 2022-03-16 — — EP disclosed
WO-2012148540-A1 COMBINATION OF KANASE INHIBITORS AND USES THREOF INTELLIKINE, LLC (US) 2012-11-01 — — WO disclosed
WO-2012116237-A2 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, LLC (US) 2012-08-30 — — WO disclosed
WO-2011149937-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, INC. (US) 2011-12-01 — — WO disclosed
WO-2011149937-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, INC. (US) 2011-12-01 — — WO disclosed
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-29 — — US disclosed
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-29 — — US disclosed
US-20100184760-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-22 — — US disclosed
US-20100184760-A1 Benzoxazole kinase inhibitors and methods of use FAETH THERAPEUTICS, INC. 2010-07-22 — — US disclosed
WO-2010051043-A1 BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2010-05-06 — — WO disclosed
WO-2010051042-A1 BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof PIK3CA, PIK3CD, PIK3CB MAPT 2704/4885LMNA 2098/4885CYP1A2 1496/4885
US-20100184760-A1 Benzoxazole kinase inhibitors and methods of use BMX, MTOR, PDPK1 MAPT 3161/4885LMNA 3015/4885CYP1A2 2043/4885
US-11547697-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB MAPT 2704/4885LMNA 2098/4885CYP1A2 1496/4885
US-20240262836-A1 NOVEL MTOR INHIBITOR COMPOUNDS MTOR, RICTOR, RPTOR MAPT 1059/4885LMNA 3419/4885CYP1A2 3090/4885
US-20100190749-A1 Benzoxazole kinase inhibitors and methods of use BMX, MTOR, PDPK1 MAPT 3161/4885LMNA 3015/4885CYP1A2 2043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.